215P Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification

Cornejo, R.A. Escala; Garcia, Melissa; Rigual-Hernández, Andrés S.; Salas, Margarita; Muñoz, María García; Ampuero, J. Claros; Pérez, L. Figuero; Martín, Eugenio Garrido; Collado, Beatriz; García, Germán Martín; Seijas-Tamayo, Raquel; Bernal, Amalia Gómez; Hernández, Juan Jesús Cruz; Sánchez, César A. Rodríguez

doi:10.1016/j.annonc.2020.08.337

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive hormonal receptor status was considered if the Estrogen Receptor (ER) or the Progesterone Receptor (PR) was ≥1%. Ki67 was classified as low if it was <20% 17 , this cut-off point apparently better for classifying subrogate subtypes 18,19 .…”

Section: Methodsmentioning

confidence: 99%

Factores predictivos de invasión en carcinoma ductal in situ diagnosticado por biopsia con aguja de corte

Villegas-Carlos

Andino-Araque²,

Valverde-Quintana

et al. 2022

CIRU

View full text Add to dashboard Cite

Objective: To identify clinical, radiological, and histopathological characteristics that could be predictive factors of microinvasive/ invasive breast carcinoma in patients with diagnosis of ductal carcinoma in situ (DCIS) by core-needle biopsy. Material and methods: This is a retrospective study conducted from 2006-2017, which included women ≥18 years of age with initial DCIS, and who were treated with surgery. Final diagnosis was divided in DCIS and microinvasive/invasive carcinoma. Results: 334 patients were included: 193 (57.8%) with DCIS and 141 (42.2%) with microinvasive/invasive carcinoma (microinvasive 5.1%, invasive 37.1%). Lymph node metastasis occurred in 16.3%. Differences between DCIS and microinvasive/invasive groups included the presence of palpable nodule (36.7% vs. 63.2%), radiological nodule (29% vs. 51%), bigger radiological-tumor size (1.2 cm vs. 1.7 cm), and larger microcalcification extension (2.5 cm vs. 3.1 cm), all of these variables p ≤0.05. Hormonal receptors and HER2 expression were similar. After logistic regression analysis, predictive factor of invasion was the presence of palpable nodule (OR = 4.072, p <0.001) and radiological multicentric disease (OR = 1.677, 95%CI = 1.036-2.716, p = 0.035). Conclusions: In patients with DCIS, palpable nodule, and radiological multicentric disease, upgrade to microinvasive/invasive is high, and sentinel lymph node is recommended.

show abstract

Section: Methodsmentioning

confidence: 99%

Factores predictivos de invasión en carcinoma ductal in situ diagnosticado por biopsia con aguja de corte

Villegas-Carlos

Andino-Araque²,

Valverde-Quintana

et al. 2022

CIRU

View full text Add to dashboard Cite

show abstract

“…Hence, the Ki-67 index helps in distinguishing between patients who may benefit from additional adjuvant therapy and those who could be spared from unnecessary interventions, although an internationally established final consensus on the Ki67 cut-off for therapeutic decisions has not been reached yet [69]. Nevertheless, a Ki67 20% cut-off is currently used to identify luminal B BC among HR+/HER2-cases, with obvious therapeutic implications [70][71][72]. According to the American Society of Clinical Oncology (ASCO) guidelines, in postmenopausal patients diagnosed with stage I-II BC, Ki67 expression might be used in combination with other clinical pathological factors to arrive at informed decisions regarding adjuvant endocrine and chemotherapy treatments when multigene assays are not accessible.…”

Section: Ki-67 Labeling Indexmentioning

confidence: 99%

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies

Pescia,

Guerini-Rocco,

Viale

et al. 2023

Cancers

View full text Add to dashboard Cite

Early breast cancer (BC) is the definition applied to breast-confined tumors with or without limited involvement of locoregional lymph nodes. While risk stratification is essential for guiding clinical decisions, it can be a complex endeavor in these patients due to the absence of comprehensive guidelines. Histopathological analysis and biomarker assessment play a pivotal role in defining patient outcomes. Traditional histological criteria such as tumor size, lymph node involvement, histological type and grade, lymphovascular invasion, and immune cell infiltration are significant prognostic indicators. In addition to the hormone receptor, HER2, and—in specific scenarios—BRCA1/2 testing, molecular subtyping through gene expression profiling provides valuable insights to tailor clinical decision-making. The emergence of “omics” technologies, applicable to both tissue and liquid biopsy samples, has broadened our arsenal for evaluating the risk of early BC. However, a pressing need remains for standardized methodologies and integrated pathological models that encompass multiple analytical dimensions. In this study, we provide a detailed examination of the existing strategies for early BC risk stratification, intending to serve as a practical guide for histopathologists and molecular pathologists.

show abstract

215P Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification

Abstract: Background: We aimed to evaluate the effect of chemotherapy (CT) and hormonal therapy (HT) on the acute toxicity of a hypofractionated radiotherapy (RT) schedule after breast conserving surgery. abstracts Annals of Oncology Volume 31 -Issue S4 -2020 S327

Cited by 2 publications

References 0 publications

Factores predictivos de invasión en carcinoma ductal in situ diagnosticado por biopsia con aguja de corte

Factores predictivos de invasión en carcinoma ductal in situ diagnosticado por biopsia con aguja de corte

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies

Contact Info

Product

Resources

About